Fifty two-week efficacy and safety results from SPIRIT-P1: A Phase 3 study of ixekizumab in patients with active psoriatic arthritis

被引：2

作者：

Mease, P. ^{[1
,2
]}

Okada, M. ^{[3
]}

Kishimoto, M. ^{[3
]}

Shuler, C. ^{[4
]}

Carlier, H. ^{[4
]}

Lin, C. ^{[4
]}

Mou, J. ^{[4
]}

Moriarty, S. R. ^{[4
]}

Lee, C. ^{[4
]}

Gladman, D. ^{[5
]}

Satler, M. ^{[6
]}

机构：

[1] Swedish Med Ctr, Seattle, WA USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] St Lukes Int Hosp, Tokyo, Japan

[4] Eli Lilly & Co, Indianapolis, IN 46285 USA

[5] Univ Toronto, Toronto, ON, Canada

[6] Eli Lilly Reg Operat GmbH, Vienna, Austria

来源：

关键词：

D O I：

10.1016/j.jid.2017.07.592

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

397

引用

页码：S260 / S260

页数：1